Alex Goldberg

Metabolix, Inc. (NASDAQ:MBLX), DARA BioSciences, Inc (NASDAQ:DARA), Affymax, Inc. (NASDAQ:AFFY), and Cadence Pharmaceuticals Inc. (NASDAQ:CADX) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 04/09/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Metabolix, Inc. (NASDAQ:MBLX), DARA BioSciences, Inc (NASDAQ:DARA), Affymax, Inc. (NASDAQ:AFFY), and Cadence Pharmaceuticals Inc. (NASDAQ:CADX).

Metabolix, Inc. (NASDAQ:MBLX) a bioscience company that develops and commercializes technologies to produce renewable alternatives to petroleum-based products comprising advanced biopolymers, biobased industrial chemicals, and bioenergy closed down in its previous session (-9.43%) on 263,804 shares traded after METABOLIX, INC. Reported its Financials. Metabolix, Inc. (NASDAQ:MBLX) is currently down (-55.31%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Metabolix, Inc. (NASDAQ:MBLX)

DARA BioSciences, Inc (NASDAQ:DARA) a development stage biopharmaceutical company that engages in the development and commercialization of oncology treatment and supportive care pharmaceutical products in the United Sates closed down in its previous session (-9.87%) on 1,370,293 shares traded after DARA BIOSCIENCES, INC. Reported its Financials. DARA BioSciences, Inc (NASDAQ:DARA) is currently down (-41.3%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about DARA BioSciences, Inc (NASDAQ:DARA)

Affymax, Inc. (NASDAQ:AFFY) a biopharmaceutical company that engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses closed down in its previous session (-6.90%) on 4,184,082 shares traded after Glancy Binkow & Goldberg LLP Announced Lead Plaintiff Deadline In The Class Action Lawsuit Against Affymax, Inc. Affymax, Inc. (NASDAQ:AFFY) is currently down (-96.25%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Affymax, Inc. (NASDAQ:AFFY)

Cadence Pharmaceuticals Inc. (NASDAQ:CADX) a biopharmaceutical company that focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates for use in the hospital setting primarily in the United States and Canada closed down in its previous session (-4.57%) on 268,306 shares traded. Cadence Pharmaceuticals Inc. (NASDAQ:CADX) is currently down (-8.42%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Cadence Pharmaceuticals Inc. (NASDAQ:CADX)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com